BioNexus Gene Lab Corp (BGLC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BGLC currently has 2.42M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 926.34% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 14, 2026 |
10-K filing | 2.4M shares outstanding |
2.4M | 0 |
| Dec 02, 2025 |
8-K filing: BioNexus Gene Lab Corp. entered into an Equity Purchase Agreement with ARC Group International Ltd. for up to $500,000,000 of the Company's common stock over a 36-month period and issued 175,000 shares of common stock to ARC as commitment shares, and also issued 392,329 shares to Fidelion as part of a Share Subscription and Shareholders' Agreement. ($0.76M proceeds) |
1.8M | 320K |
| Nov 14, 2025 |
10-Q filing | 1.8M shares outstanding |
1.8M | 320K |
| Nov 07, 2025 |
S-3 filing: The company is filing an S-3 to register the offering of common stock and preferred stock, with a total aggregate amount of up to $100,000,000. |
1.8M | 320K |
| May 15, 2025 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Apr 15, 2025 |
10-K filing | 17.8M shares outstanding |
18M | 0 |
| Apr 07, 2025 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 17,967,663 → 1,796,597 |
1.8M | 0 |
| Feb 14, 2025 |
8-K filing: The company filed an amendment to its Articles of Incorporation to authorize the creation of one share of Series Z Convertible Preferred Stock, which has 5 billion votes and is intended to facilitate a reverse stock split. |
18M | 0 |
| Nov 15, 2024 |
10-Q filing | 18.0M shares outstanding |
18M | 0 |
| Aug 26, 2024 |
8-K filing: BioNexus Gene Lab Corp., through its subsidiary, invested approximately USD 228k to acquire a significant equity stake in Ascension Innovation Sdn Bhd by subscribing to 10,758 units of Ordinary Shares in AISB. ($0.23M proceeds) |
18M | 0 |
| Aug 14, 2024 |
10-Q filing | 18.0M shares outstanding |
18M | 0 |
| May 15, 2024 |
10-Q filing | 17.7M shares outstanding |
18M | 0 |
| Apr 16, 2024 |
10-K filing | 17.7M shares outstanding |
18M | 0 |
| Aug 16, 2023 |
10-Q filing | 171.2M shares outstanding |
170M | 0 |
| Jul 24, 2023 |
8-K filing: BioNexus Gene Lab Corp. closed a public offering of 1,437,500 shares of common stock at $4.00 per share, resulting in gross proceeds of $5.75 million, and issued warrants to the underwriter to purchase 115,000 shares at $4.40 per share. The company also amended its bylaws to increase the maximum number of directors from seven to nine. ($5.75M proceeds) |
14M | 330K |
| Jul 20, 2023 |
Stock Split
8-K filing: Stock split 1-for-12 | Outstanding: 171,218,152 → 14,262,472 |
14M | 330K |
| Jul 17, 2023 |
S-1/A filing: This is an S-1/A filing for a common stock offering with an over-allotment option. The purchase price per share is $4.00, and the underwriter's warrants are exercisable at 110% of the public offering price. |
170M | 3.9M |
| Jul 05, 2023 |
S-1/A filing: BioNexus Gene Lab Corp is offering up to an aggregate of 1,250,000 shares of its common stock on a firm commitment basis. |
170M | 3.9M |
| May 09, 2023 |
S-1/A filing: BioNexus Gene Lab Corp is offering up to 1,875,000 shares of common stock on a firm commitment basis, with an underwriter option to purchase up to an additional 281,250 shares. |
170M | 2.2M |
| May 09, 2023 |
10-Q filing | 171.2M shares outstanding |
170M | 4.7M |
| Mar 31, 2023 |
10-K filing | 173.7M shares outstanding |
170M | 0 |
| Feb 14, 2023 |
S-1 filing: This is an S-1 filing related to a common stock offering underwritten by Network 1 Financial Securities, Inc. and includes an over-allotment option. Additionally, representative warrants will be issued to Network 1 Financial Securities, Inc. |
170M | 0 |
| Nov 14, 2022 |
10-Q filing | 173.7M shares outstanding |
170M | 0 |
| Aug 15, 2022 |
10-Q filing | 173.7M shares outstanding |
170M | 0 |
| May 16, 2022 |
10-Q filing | 171.2M shares outstanding |
170M | 0 |
| Apr 06, 2022 |
10-K filing | 171.2M shares outstanding |
170M | 0 |
| Nov 15, 2021 |
10-Q filing | 171.2M shares outstanding |
170M | 0 |
| Aug 12, 2021 |
10-Q filing | 171.2M shares outstanding |
170M | 0 |
| May 18, 2021 |
10-Q filing | 171.2M shares outstanding |
170M | 0 |
| Mar 30, 2021 |
10-K filing | 171.2M shares outstanding |
170M | 0 |
| Dec 30, 2020 |
8-K filing: BioNexus Gene Lab Corp acquired Chemrex Corporation Sdn. Bhd. in exchange for 68,487,261 shares of common stock of BioNexus. |
100M | 0 |
| Nov 03, 2020 |
10-Q filing | 102.7M shares outstanding |
100M | 0 |
| Aug 11, 2020 |
10-Q filing | 102.7M shares outstanding |
100M | 0 |
| May 08, 2020 |
10-Q filing | 102.7M shares outstanding |
100M | 0 |
| Mar 31, 2020 |
10-K filing | 102.7M shares outstanding |
100M | 0 |